
Global R&D Pipeline
My Favorite
Hot Targets:
LY6G6D
Back
Total number of drugs
2
Phase II and later clinical stages
0%
Involving companies
2
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-LY6G6D Single-Domain Antibody(Hongcheng Biopharma) | Anti-LY6G6D Single-Domain Antibody(Hongcheng Biopharma) | Nanobody | Neoplasms Digestive System Disorders | lymphocyte antigen 6 family member G6D inhibitors | Shanghai Hongcheng Pharmaceutical Co. Ltd. | Shanghai Hongcheng Pharmaceutical Co. Ltd. | Preclinical | Preclinical | Anti-LY6G6D Single-Domain Antibody(Hongcheng Biopharma) | detail > | |||||||||||
| IMD-2206 | IMD-2206 | Antibody drug conjugate (ADC) ADC | Neoplasms | lymphocyte antigen 6 family member G6D inhibitors | Shanghai Affinity Biopharmaceutical Co., Ltd. | Preclinical | Preclinical | IMD-2206 | detail > |
Total 2 data
1


